BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21712498)

  • 1. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
    Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
    J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
    Kiser JJ; Gerber JG; Predhomme JA; Wolfe P; Flynn DM; Hoody DW
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):570-8. PubMed ID: 18176327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
    Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
    Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
    Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
    Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
    Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD; Dane AL; Schneck DW; Warwick MJ
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
    Martin PD; Warwick MJ; Dane AL; Cantarini MV
    Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
    Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD; Mitchell PD; Schneck DW
    Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults.
    Gosai P; Liu J; Doyle RT; Johnson J; Carter R; Sica D; McKenney JM
    Expert Opin Pharmacother; 2008 Dec; 9(17):2947-53. PubMed ID: 19006471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
    Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
    Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.